Eicosapentaenoic acid

二十碳五烯酸

Report date: 2024/11/22 20:00:28

Base Information

Drug NameEicosapentaenoic acid
Drug Alias NameIcosapentALFAEPAEPA-FFA
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionThromboxane A2 synthase inhibitors
TargetsThromboxane A2 synthase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Autism Spectrum DisorderDepressive Disorder, Treatment-Resistant +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited KingdomSpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator Companies1 A Pharma Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesUtah State UniversityNational Institutes Of HealthNational Center For Complementary And Integrative Health +[5] 
Inactive CompaniesS. L. A. Pharma Ag
Active IndicationsAutism Spectrum DisorderDepressive Disorder, Treatment-ResistantOverweight +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Adenomatous Polyposis Coli

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG